Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
Early Phase 1
Not yet recruiting
- Conditions
- High-Grade Glioma
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 39
- Registration Number
- NCT06829173
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients
Phase 1
Completed
- Conditions
- MetastasisLocally Advanced Solid TumorRecurrent Cancer
- Interventions
- Radiation: Palliative radiotherapy
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- XRad Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT05002140
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Stanford Clinical Cancer Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath